期刊文献+

肢端肥大症的垂体腺瘤继发糖尿病的相关因素分析 被引量:2

Analysis of factors related to diabetes secondary to pituitary adenoma with acromegaly
下载PDF
导出
摘要 目的探讨肢端肥大症的垂体腺瘤病人继发糖尿病的相关因素。方法回顾性分析继发与未继发糖尿病的84例肢端肥大症垂体腺瘤病人在发病年龄、性别、时间、瘤体大小、术前血生长激素(GH)及激素免疫组化方面的不同,采用二分类多因素Logistic回归分析肢端肥大症垂体腺瘤病人继发糖尿病的相关因素。结果与未继发糖尿病比较,继发糖尿病的肢端肥大症垂体腺瘤病人的发病时间更短,术前血GH更高,促甲状腺激素(TSH)免疫反应阳性率更高(P<0.05)。Logistic回归分析统计结果显示:发病时间、术前血GH水平及TSH免疫阳性率的Exp(B)值分别为0.212、1.160、93.392(P<0.05)。结论发病时间、术前血GH及TSH免疫阳性是肢端肥大症垂体腺瘤继发糖尿病的相关因素,TSH免疫阳性是主要因素;肿瘤分泌的TSH可能参与肢端肥大症垂体腺瘤继发糖尿病的病理生理过程。 Objective To explore the factors related to diabetes secondary to pituitary adenoma with acromegaly. Methods Clinical data of 84 acromegalic pituitary adenoma patients with or without secondary diabetes were analyzed retrospectively. The differences were compared between patients with and without secondary diabetes in the age, sex, occurrence time, tumor size, preoperative blood growth hormone(GH) level and tumor immune response. The factors related to diabetes secondary to acromegalic pituitary adenoma were analyzed by two classification of multifactor logistic regression. Results Compared with the patients without diabetes, the occurrence time was shorter, the preoperative blood GH and percentage of positive thyroid stimulation hormone(TSH) immunoreactivity were higher(P〈0.05) in the patients with diabetes. Logistic regression results showed that Exp(B) of the occurrence time, preoperative blood GH and percentage of positive TSH immunoreactivity were 0.212, 1.160, 93.392(P〈0.05). Conclusions The occurrence time,preoperative blood GH and TSH positive immune response rate are the factors related to diabetes secondary to acromegalic pituitary adenoma. TSH positive immune response is the main factor. TSH secreted by tumor cells may be involved in the pathological and physiological process of acromegalic pituitary adenoma with secondary diabetes.
出处 《中国微侵袭神经外科杂志》 CAS 2015年第5期211-213,共3页 Chinese Journal of Minimally Invasive Neurosurgery
关键词 肢端肥大症 垂体肿瘤 糖尿病 促甲状腺激素 相关分析 acromegaly pituitary neoplasms diabetes mellitus thyrotropin correlation analysis
  • 相关文献

参考文献10

  • 1中国肢端肥大症诊治指南(2013版)[J].中华医学杂志,2013,93(27):2106-2111. 被引量:44
  • 2王海军,毛志钢,何东升.垂体腺瘤经蝶窦手术治疗进展[J].中国微侵袭神经外科杂志,2013,18(1):1-4. 被引量:24
  • 3Ayuk J,Sheppard MC.Does acromegaly enhance mortality[J]?Rev Endocr Metab Disord,2008,9(1):33-39.
  • 4Melmed S,Casanueva FF,Klibanski A,et al.A consensus on the diagnosis and treatmen t of acromegaly complications[J].Pituitary,2013,16(3):294-302.
  • 5Alexopoulou O,Bex M,Kamenicky P,et al.Prevalence and risk factors of impaired glucose tolerance and diabetes mellitus at diagnosis of acromegaly:a study in 148 patients[J].Pituitary,2014,17(1):81-89.
  • 6Fieffe S,Morange I,Petrossians P,et al.Diabetes in acromegaly,prevalence,risk factors,and evolution:data from the French Acromegaly Registry[J].Eur J Endocrinol2011,164(6):877-884.
  • 7王晓红,靳桂明,吴笑春.成人肺部感染患者健康等级及住院费用Logistic回归分析[J].中华医院感染学杂志,2004,14(11):1229-1231. 被引量:11
  • 8Chubb SA,Davis WA,Davis TM.Interactions among thyroid function,Insulin se nsitivity,and serum lipid concentrations:the Fremantle diabetes study[J].J Clin Endocrinol Metab,2005,90(9):5317-5320.
  • 9Dagdelen S,Cinar N,Erbas T.Increased thyroid cancer risk in acromegaly[J].Pituitary,2014,17(4):299-306.
  • 10Vallette S,Ezzat S,Chik C,et al.Emerging trends in the diagnosis and treatment of acromegaly in Canada[J].Clin Endocrinol(Oxf),2013,79(1):79-85.

二级参考文献33

  • 1王任直,任祖渊,苏长保,杨义,陶蔚,马文斌,尹剑.采用扩大经蝶窦入路方法切除鞍区和斜坡巨大肿瘤[J].中华医学杂志,2004,84(20):1693-1697. 被引量:21
  • 2吴进军.住院构成前10位病种医疗费用的Logistic分析[J].中国卫生资源,2000,3(1):19-20. 被引量:4
  • 3毛志钢,王海军,何东升,陈明振,杨超,蓝海.经蝶显微手术治疗哑铃形垂体腺瘤(附33例报告)[J].中国神经精神疾病杂志,2005,31(5):376-378. 被引量:4
  • 4李士其,王镛斐,赵曜,寿雪飞,贾丕枫.经蝶显微手术治疗垂体腺瘤3375例[J].中国临床神经外科杂志,2005,10(6):403-406. 被引量:35
  • 5Katznelson L, Atkinson JL, Cook DM, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly- 2011 update. Endocr Pract, 2011, 17 Suppl 4:1-44.
  • 6Giustina A, Barkan A, Casanueva FF, et al. Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab, 2000, 85:526-529.
  • 7Melmed S, Casanueva FF, Cavagnini F, et al. Guidelines for acromegaly management. J Clin Endocrinol Metab, 2002, 87: 4054-4058.
  • 8Brabant G, von zur Mtihlen A, Wtister C, et al (German KIMS Board). Serum insulin-like growth factor I reference values for an automated chemiluminescence immunoassay system: results from a muhicenter study. Horm Res, 2003, 60:53-60.
  • 9Giustina A, Casanueva FF, Cavagnini F, et al. Diagnosis and treatment of acromegaly complications. J Endocrinol Invest, 2003, 26 : 1242-1247.
  • 10Nomikos P, Buchfelder M, Fahlbusch R. The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical "cure". Eur J Endocrinol,2005, 152 : 379-387.

共引文献76

同被引文献9

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部